Literature DB >> 20726769

The beginning of a new era in understanding hepatitis C virus prevention.

Josiah D Rich, Lynn E Taylor.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20726769      PMCID： PMC2936237          DOI： 10.1086/656213

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  24 in total

1.  Survival of HIV-1 in syringes: effects of temperature during storage.

Authors:  N Abdala; R Reyes; J M Carney; R Heimer
Journal:  Subst Use Misuse       Date:  2000-08       Impact factor: 2.164

2.  Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-04-19

3.  Survival of HIV-1 in syringes.

Authors:  N Abdala; P C Stephens; B P Griffith; R Heimer
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-01-01

4.  Surprisingly small effect of antiviral treatment in patients with hepatitis C.

Authors:  Yngve Falck-Ytter; Hemangi Kale; Kevin D Mullen; Steedman A Sarbah; Lucian Sorescu; Arthur J McCullough
Journal:  Ann Intern Med       Date:  2002-02-19       Impact factor: 25.391

Review 5.  Epidemiology of hepatitis C.

Authors:  M J Alter
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

6.  Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008.

Authors:  Gayle E Fischer; Melissa K Schaefer; Brian J Labus; Lawrence Sands; Patricia Rowley; Ihsan A Azzam; Patricia Armour; Yury E Khudyakov; Yulin Lin; Guoliang Xia; Priti R Patel; Joseph F Perz; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

7.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

8.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.

Authors:  C Frank; M K Mohamed; G T Strickland; D Lavanchy; R R Arthur; L S Magder; T El Khoby; Y Abdel-Wahab; E S Aly Ohn; W Anwar; I Sallam
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

9.  Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection.

Authors:  Dawn A Fishbein; Yungtai Lo; John F Reinus; Marc N Gourevitch; Robert S Klein
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

10.  Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.

Authors:  Catherine A Fleming; Donald E Craven; David Thornton; Sheila Tumilty; David Nunes
Journal:  Clin Infect Dis       Date:  2002-12-11       Impact factor: 9.079
View more
  3 in total

1.  Inactivation and survival of hepatitis C virus on inanimate surfaces.

Authors:  Juliane Doerrbecker; Martina Friesland; Sandra Ciesek; Thomas J Erichsen; Pedro Mateu-Gelabert; Jörg Steinmann; Jochen Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

Review 2.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

3.  The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.

Authors:  Jeffrey B Joy; Rosemary M McCloskey; Thuy Nguyen; Richard H Liang; Yury Khudyakov; Andrea Olmstead; Mel Krajden; John W Ward; P Richard Harrigan; Julio S G Montaner; Art F Y Poon
Journal:  Lancet Infect Dis       Date:  2016-03-30       Impact factor: 25.071
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.